Rocket Lab Stock Gained 118% Over the Past Year. Is It Time to Buy?

Rocket Lab agreed to buy Iridium in an ~$8B, half-stock/half-cash deal to expand satellite communications, expected to close in 1H 2027. In parallel, it posted a strong Q1 2026 with sales up nearly 64% to $200M and losses narrowing to $0.07/share vs ~$0.08/share consensus, with 31 additional launch contracts signed in Q1. However, investors face risks from potential Neutron launch delays and the company’s ongoing unprofitability ($45M Q1 loss) alongside a very high 82x price-to-sales valuation (vs tech avg ~9x).

Analysis

Near term, the market should treat this as a valuation event more than a pure fundamentals event: RKLB is being asked to absorb a profitable but lower-growth asset while still funding a capital-intensive launch roadmap. That combination usually increases the equity overhang, because the acquirer gets credited for strategic breadth before investors have proof that added earnings can offset dilution, leverage, and integration complexity.

The biggest second-order effect is on financing quality. If management has to lean on stock, the deal becomes a slow-moving dilution story; if it leans on debt, the market will immediately re-rate RKLB as a balance-sheet risk rather than a pure growth compounder. IRDM is likely to trade as a merger-spread instrument, so the key driver over the next 1-3 months is not space sentiment but clarity on regulatory path, financing mix, and any signs that the deal economics are being re-traded.

The consensus is missing how crowded the "next SpaceX" narrative has become: RKLB already trades on future optionality, so any miss on Neutron or any delay in converting bookings into launch cadence can compress the multiple faster than revenue growth can expand it. Over 6-18 months, the bullish case depends on turning government demand into recurring, higher-margin execution; if that does not show up, the market may decide the story is too expensive even if the top line keeps growing. The main falsifier is a clean Neutron test plus improved cash conversion without meaningful dilution; absent that, the stock remains vulnerable to de-rating on any operational slip.

Key Decisions for Investors

• Prefer a relative-value long IRDM / short RKLB position into the deal-review window: target the spread if financing terms or regulatory timing create uncertainty, with the hedge protecting against a broad space-theme rally.
• Do not chase RKLB after momentum; wait for either a post-Neutron-test setup or a 10-15% pullback. The risk/reward is poor at a premium multiple unless execution de-risks the roadmap.
• If you want upside exposure to the space theme, use SPCX only as a small basket proxy and pair it against a short in the highest-multiple space names. The theme can stay hot while individual equities re-rate lower on dilution concerns.
• Use a conditional alert on RKLB: if Neutron slips materially or financing looks more stock-heavy than expected, treat that as a catalyst to short rallies, since the stock is priced for uninterrupted execution.
• For event-driven accounts, consider IRDM shares only as a spread trade, not a directional long: upside is capped by deal terms, while downside is driven mainly by closing risk rather than operating fundamentals.